Please assess the completion status of the following clinical trial:

Trial Title: The Mochudi Prevention Project ART Protocol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection~* CD4 cell count ≥ 250 cells/mm3~* HIV-1 RNA ≥ 50,000 cp/mL~* No AIDS-defining illness or other illness that would cause volunteer to be eligible for ART through the Botswana National Program (these volunteers should be referred to the National Program for treatment)~* Age 16 to 64 years~* Botswana citizen~* Resident of the north-east segment of Mochudi~* The following laboratory values obtained within 60 days prior to study enrollment:~  * Absolute neutrophil count (ANC) ≥ 500 cells/mm3.~ * Hemoglobin ≥ 7.0 g/dL.~ * AST (SGOT), ALT (SGPT), and bilirubin ≤ 5 X ULN. Note: if the estimated creatinine clearance (by Cockgroft-Gault equation) is \<60 mL/min, then TDF/FTC will be substituted with ZDV/3TC~* Ability to swallow oral medications.~* Ability and willingness of participant to give informed consent (or in case of participants \< 18 years of age, ability and willingness to provide assent; and for parent/guardian to provide consent).~* Not currently involuntarily incarcerated.~* Karnofsky performance score ≥ 70 at time of study enrollment.~* If participating in sexual activity that could lead to pregnancy and of reproductive potential, female participants must use two reliable methods of contraception simultaneously, one of which must be a barrier method, while receiving protocol-specified medications, and for 12 weeks after stopping the medications.~* For participants \< 18 years of age: Weight of 40kg or more~Exclusion Criteria:~* Receipt at any time prior to study enrollment of \> 7 days cumulative treatment with any ARV or combination of ARVs (except ARVs taken for any length of time during pregnancy for the prevention of mother-to-child transmission (pMTCT) or ARVs taken for occupational exposure).~* Current receipt of 3-drug ART for pMTCT~* Allergy/sensitivity to any study drug or its formulations.~* Acute therapy for serious medical illnesses, in the opinion of the site investigator, within 14 days prior to enrollment.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).